Clinical Trial Update: A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer [Phase 2, Phase 3]

View source ↗

Summary

A study of methylnaltrexone bromide (MNTX) in advanced pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Methylnaltrexone bromide (methylnaltrexone bromide)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Pancreatic Cancer | Phase 2, Phase 3 | Status: WITHDRAWN